Nuvation Bio Reports Q1 Growth as Iptrozy Moves Earlier in ROS1 Lung Cancer Care

Overview

• Nuvation posted $83.2 million in total Q1 revenue, with $18.5 million from U.S. Iptrozy sales that rose 18% from the prior quarter.
• About 200 patients started Iptrozy in the quarter and, for the first time, more than half were new to ROS1 drugs, reflecting a shift toward first-line use.
• Management said revenue is building as more first-line patients stay on therapy longer, a compounding effect that occurs when durable responders remain on treatment month after month.
• Updated pooled TRUST studies reported roughly 50 months of tumor control in first-line patients and strong brain activity, and the drug is now listed in NCCN guidance for ROS1 lung cancer with brain metastases.
• Nuvation recognized $64.7 million in collaboration revenue, ended the quarter with $533.7 million in cash, secured rights to the glioma drug safusitinib in Japan with plans to add sites there, and guided that discounts are likely to settle near 30% with a potential $30 million Europe milestone in 2027.